Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q2 2021 · 10-Q
Revenue—
Net Income-$13.11M-$13.11MN/M vs Q2 2020 EPS Diluted-$0.09-$0.09N/M vs Q2 2020 Operating Income-$12,625,284N/M Operating Cash Flowderived-$11,746,159N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 14, 2021 · 44 d after period end